Struggling for a Cure: The Financial Roadblocks of Gene Therapy for Rare Diseases

Robin Alderman's quest for a gene therapy to cure her son Camden's rare immune deficiency has faced significant financial hurdles. London-based Orchard Therapeutics ceased its experimental treatment for Wiskott-Aldrich syndrome, leaving many families in despair. Worldwide, millions suffer from rare genetic diseases, yet financial incentives for treatments are lacking.

Robin Alderman faces a grim reality: gene therapy might cure her son Camden's rare genetic immune deficiency, but it remains out of reach.

In 2022, London-based Orchard Therapeutics halted its experimental treatment for Wiskott-Aldrich syndrome, a decision that left many families grappling for alternatives. For Robin, who has been her 21-year-old son's advocate since birth, the news was devastating.

Approximately 350 million people worldwide are affected by rare diseases, most of which are genetic. But with each condition affecting only a tiny fraction of the population, commercial incentives for one-time gene therapy solutions are scant. Families like the Aldermans find themselves turning to DIY fundraising for potential cures, often with slim chances of success.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)